ArticleAntimicrobial agents and chemotherapy2025
Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity.
Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploration of zileuton protective mechanisms against vancomycin-associated nephrotoxicity.Toxicology and applied pharmacology · 2025Article
- Protection against vancomycin-associated nephrotoxicity by zileuton: role of mitochondria revealed by electron microscopic study.Ultrastructural pathology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glycopeptide, polymyxin, and aminoglycoside antibiotics are among the most commonly used agents to treat drug-resistant bacterial infections; however, their clinical use is hindered by nephrotoxicity. We previously reported that zileuton has the potential to attenuate antibiotic-associated nephrotoxicity in an animal model. Here, we further report the development of a parenteral formulation and exploration of dosing strategies for zileuton. The solubility, stability, and multi-dose safety of two zileuton formulations were evaluated. Zileuton serum and renal tissue pharmacokinetics were evaluated after a single dose and compared to steady state after 10 days. Different dosing strategies of zileuton to attenuate vancomycin-, polymyxin B-, and amikacin-associated nephrotoxicity were evaluated in rats over 10 days. Two formulations (1 and 10 mg/mL) showed good multi-dose safety, with no significant changes in serum creatinine, alanine transaminase, or body weight observed following doses of 12 mg/kg daily for 10 days. Zileuton was well-distributed into renal tissue, and serum exposure was comparable to humans after a typical dose (600-2,400 mg). No drug accumulation at steady state was observed. Zileuton was found to reduce nephrotoxicity associated with vancomycin, polymyxin B, and amikacin in a dose-dependent manner. With the same daily dose, dose fractionation resulted in similar renal protection compared to once-daily dosing. These preliminary studies support that zileuton has the potential to be used as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. This would allow the optimal use of glycopeptides, polymyxins, and aminoglycosides to treat difficult infections. Further studies are warranted to repurpose zileuton as a nephroprotectant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.